Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties

John A. Christopher, Sarah J. Aves, Jason Brown, James C. Errey, Suki S. Klair, Christopher J. Langmead, Oliver J. Mace, Richard Mould, Jayesh C. Patel, Benjamin G. Tehan, Andrei Zhukov, Fiona H. Marshall, Miles Congreve

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

A novel series of potent, selective, and orally efficacious dual antagonists of the orexin receptors has been investigated, resulting in the identification of lead compound 27 (HTL6641). Comprehensive data for 27 are presented, including in vivo PK parameters, confirmation of receptor occupancy through ex vivo binding and efficacy in a rat sleep model. A key feature of the series is a short dissociation half-life, measured by surface plasmon resonance (SPR) using stabilized receptors, and confirmed by radioligand-binding experiments. Based on a consideration of the requirements for a potential treatment for insomnia, compound 27 was identified as having the best balance of properties from the chemical series.

Original languageEnglish
Pages (from-to)947-955
Number of pages9
JournalMedChemComm
Volume6
Issue number5
DOIs
Publication statusPublished - 1 May 2015

Cite this

Christopher, J. A., Aves, S. J., Brown, J., Errey, J. C., Klair, S. S., Langmead, C. J., Mace, O. J., Mould, R., Patel, J. C., Tehan, B. G., Zhukov, A., Marshall, F. H., & Congreve, M. (2015). Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. MedChemComm, 6(5), 947-955. https://doi.org/10.1039/c5md00027k